Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

Front Oncol · 2018 · PMC5994406 · PMID 29915719

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

The study showed that increasing the rituximab dose from 375 to 500 mg/m 2 , given every 14 days for six cycles, led to a 32.5% increase in PFS and a 30% increase in OS, although OS increase did not achieve significance ( 28 ).

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.